Lurasidone Reactions 1680, p213 - 2 Dec 2017 Tardive dyskinesia: case report A 33-year-old woman developed tardive dyskinesia (TD) during treatment with lurasidone [route not stated]. The woman, who had a history of generalised anxiety disorder, bipolar disorder and post-traumatic stress disorder, presented with the symptoms of irritability, decreased interest, low mood, poor concentration and low energy. She was receiving clonidine, lithium and lorazepam for anxiety treatment. In addition to this, lurasidone 20mg added for bipolar depression. In the subsequent months, lurasidone dose was increased to 60mg at bedtime (HS). She also received benzatropine for the prophylaxis of extrapyramidal symptoms (EPS). Later, she was lost to follow up and stopped the medication for 2 months. Upon her return, she again received lurasidone 40mg HS along with lithium for bipolar depression. She also received clonazepam and benzatropine for anxiety and EPS prophylaxis, respectively. Lithium and benzatropine were stopped because of nausea and double vision. Clonazepam therapy was stopped because of poor response. Then, she received eszopiclone and gabapentin for sleep and anxiety, respectively. Her lurasidone dose was increased to 60mg at bedtime, and 9 weeks after the lurasidone therapy re-initiation, she experienced involuntary tongue movements. Then, lurasidone induced TD was suspected. Subsequently, the woman’s lurasidone therapy was stopped in the following weeks, and her clonazepam therapy was re- initiated. Ten weeks after the lurasidone discontinuation, her TD symptoms disappeared. Author comment: "Here we report a case of lurasidone- induced TD." "In our case, TD symptoms remitted 10 weeks after discontinuation of lurasidone. Clinically this case exemplifies early identification of TD and discontinuation of offending agent as potentially reversing the course of TD." Sinha S, et al. Tardive dyskinesia in the era of second generation antipsychotics: A case report and literature review. CNS Spectrums 21: 98-99 (plus poster), No. 1, 22 Feb 2016. Available from: URL: [abstract] - USA 803284802 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 Reactions Weekly Springer Journals


Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
1 page

Loading next page...
1 Page
Springer International Publishing
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
Publisher site
See Article on Publisher Site

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.

DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches


Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.



billed annually
Start Free Trial

14-day Free Trial